ArticlesArchiveAboutEditorial BoardAuthor Guidelines
Call for papersThe 2026 special issue on Climate & Health is open for submissions.Learn more
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En…
Teruo Miyazaki, Tadashi Ikegami, Yoshiaki Nagai, Amy Nguyen, Yasushi Matsuzaki, Kunihiko Kobayashi, Susan Ceryak
The anti-cancer therapy of irinotecan (CPT-11) is often limited due to severe late-onset diarrhea. Because the higher toxic form of CPT-11/its active metabolite (SN-38) is produced at acidification, the usefulness of oral sodium bicarbon ate treatment against…
Adi Prayitno, Elyana Asnar, Suhartono Taat Putra
Introduction: Now the molecular epidemiology is a new experience. It’s was noted that n inety percent of mouth canc ers are squamous cell carcinomas and recorded 0.96% year of all cancers in Indonesia. Human papilloma virus (HPV) was implicated in pathogenesi…
Lei Li, Pei Zhang, Haibin Wei, Weicang Wang, Liangfang Yao, Yubing Li, Lei Zhou, Zhuo Wang, Jiang Liu, Li Zhou, Ali Amjad, Bianhong Zhang, Tiantian Jing, Jianru Xiao, Yongyan Dang, Xiaotao Li
p 21 Waf/Cip1 , p16 INK4a and p14 ARF (p19 ARF in mice) have been demonstrated to be degraded by REG γ -proteasome pathway in an ATP- and ubiquitin-independent manner in vitro . However, the in vivo roles of REG γ mediated-degradation of p21 Waf/Cip1 , p16 IN…
Kimiko Ishiguro, Krishnamurthy Shyam, Philip G. Penketh, Raymond P. Baumann, Alan C. Sartorelli, Thomas J. Rutherford, Elena S. Ratner
The tumor selectivity of alkylating agents that produce guanine O 6 -chloroethyl (laromustine and carmustine) and O 6 -methyl (temozolomide) lesions depends upon O 6 -methylguanine-DNA methyltransferase (MGMT) activity being lower in tumor than in host tissue…
Dominique R. Talbert, Robert L. Wappel, Diarmuid M. Moran, Scott A. Shell, Sarah S. Bacus
In recent years histone deacetylase inhibitors (HDACi’s) have emerged as promising therapeutics for cancer. While favorable responses to HDACi’s as single agents have been shown in several hematological malignancies, very little efficacy has been demonstrated…
Harvey Bumpers, Ming-Bo Huang, Venkat Katkoori, Upender Manne, Vincent Bond
Results from studies with animal models suggest that, in many cancers, CXCR4 is an important therapeutic target and that CXCR4 antagonists may be promising treatments for primary cancers and for metastases. The Nef protein effec tively competes with CXCR4’s n…
Naoki Anbo, Kazuhiro Ogi, Yohei Sogabe, Makoto Shimanishi, Takeshi Kaneko, Hironari Dehari, Akihiro Miyazaki, Hiroyoshi Hiratsuka
Object: Hypoxia occurs when oxygen tension drops below normal limits, and malignant tumors often experience hy poxia, which activates the expression of genes through oxygen-sensitive transcription factors, including the hypoxia inducible factor (HIF) and the…
Ka-To Shum, Jiehua Zhou, John J. Rossi
Lymphomas are cancers that arise from white blood cells and usually present as solid tumors. Treatment of lymphoma often involves chemotherapy, and can also include radiotherapy and/or bone marrow transplantation. There is an un questioned need for more effec…
Rashida A. Karmali, Yulia Maxuitenko, Greg Gorman
Background: Paclitaxel (PTX) is approved for the treatment of refractory ovarian cancer and breast cancer, but is problematic due to severe, dose-dependent, potentially irreversible neurotoxicity. Alternative formulations using nanoparticles and liposomes hav…
Zeina Nahleh, Juan E. Arenas, Arafat Tfayli
Sex steroids, also known as sex hormones are synthesized naturally by the gonads (ovaries or testes). The two main classes of sex steroids, androgens and estrogens, are crucial hormones for the proper development and function of the body; they regulate sexual…
No articles in this issue.
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En… All articles are open access under a CC BY 4.0 licence, with authors retaining copyright.
Authors submit their manuscript, metadata, and declarations through the portal. There is no submission fee.
The editorial office screens the manuscript for scope, completeness, and formatting before assigning a handling editor.
At least two independent reviewers evaluate the manuscript under single-blind review. Where revisions are required, authors respond point by point.
On acceptance the article processing charge is invoiced and the CC BY 4.0 copyright handover is signed.
The article is copyedited, typeset, and given a DOI, then publishes open access with a permanent link.
Manuscripts must be original and not under consideration elsewhere. Submit in Microsoft Word or LaTeX with figures at 300 dpi minimum. Structure research articles as Abstract, Introduction, Methods, Results, Discussion, and References.
Use the journal's numbered (Vancouver) reference style. Cite sources consecutively in the order they appear, and ensure every reference is complete and retrievable.
Declare all funding sources, conflicts of interest, and ethical approvals (including informed consent and animal-care statements where applicable).